-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Surge Not Quite Adding Up
China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Surge Not Quite Adding Up
The China Biotech Services Holdings Limited (HKG:8037) share price has done very well over the last month, posting an excellent gain of 35%. Notwithstanding the latest gain, the annual share price return of 9.9% isn't as impressive.
After such a large jump in price, China Biotech Services Holdings' price-to-earnings (or "P/E") ratio of 34.7x might make it look like a strong sell right now compared to the market in Hong Kong, where around half of the companies have P/E ratios below 9x and even P/E's below 5x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
For example, consider that China Biotech Services Holdings' financial performance has been poor lately as it's earnings have been in decline. One possibility is that the P/E is high because investors think the company will still do enough to outperform the broader market in the near future. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
Check out our latest analysis for China Biotech Services Holdings
SEHK:8037 Price Based on Past Earnings June 28th 2022 Want the full picture on earnings, revenue and cash flow for the company? Then our free report on China Biotech Services Holdings will help you shine a light on its historical performance.Is There Enough Growth For China Biotech Services Holdings?
There's an inherent assumption that a company should far outperform the market for P/E ratios like China Biotech Services Holdings' to be considered reasonable.
Retrospectively, the last year delivered a frustrating 2.6% decrease to the company's bottom line. At least EPS has managed not to go completely backwards from three years ago in aggregate, thanks to the earlier period of growth. Accordingly, shareholders probably wouldn't have been overly satisfied with the unstable medium-term growth rates.
Comparing that to the market, which is predicted to deliver 16% growth in the next 12 months, the company's momentum is weaker based on recent medium-term annualised earnings results.
With this information, we find it concerning that China Biotech Services Holdings is trading at a P/E higher than the market. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. There's a good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with recent growth rates.
What We Can Learn From China Biotech Services Holdings' P/E?
China Biotech Services Holdings' P/E is flying high just like its stock has during the last month. While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.
Our examination of China Biotech Services Holdings revealed its three-year earnings trends aren't impacting its high P/E anywhere near as much as we would have predicted, given they look worse than current market expectations. Right now we are increasingly uncomfortable with the high P/E as this earnings performance isn't likely to support such positive sentiment for long. Unless the recent medium-term conditions improve markedly, it's very challenging to accept these prices as being reasonable.
Don't forget that there may be other risks. For instance, we've identified 1 warning sign for China Biotech Services Holdings that you should be aware of.
If you're unsure about the strength of China Biotech Services Holdings' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The China Biotech Services Holdings Limited (HKG:8037) share price has done very well over the last month, posting an excellent gain of 35%. Notwithstanding the latest gain, the annual share price return of 9.9% isn't as impressive.
這個中國生物科技服務控股有限公司(HKG:8037)股價在過去一個月表現非常出色,錄得35%的出色漲幅。儘管最近股價上漲,但9.9%的年度股價回報率並不令人印象深刻。
After such a large jump in price, China Biotech Services Holdings' price-to-earnings (or "P/E") ratio of 34.7x might make it look like a strong sell right now compared to the market in Hong Kong, where around half of the companies have P/E ratios below 9x and even P/E's below 5x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
經過如此大的漲幅後,中國生物科技控股有限公司34.7倍的市盈率可能會讓它現在看起來像是一個強勁的賣盤。在香港,大約一半的公司的市盈率低於9倍,甚至低於5倍的市盈率也很常見。然而,僅僅從表面上看待市盈率是不明智的,因為可能會有一個解釋,為什麼它如此之高。
For example, consider that China Biotech Services Holdings' financial performance has been poor lately as it's earnings have been in decline. One possibility is that the P/E is high because investors think the company will still do enough to outperform the broader market in the near future. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
例如,考慮到中國生物技術服務控股公司最近的財務表現一直不佳,因為它的收益一直在下降。一種可能性是,市盈率很高,因為投資者認為該公司在不久的將來仍將採取足夠的措施來跑贏大盤。你真的希望如此,否則你會無緣無故地付出相當大的代價。
Check out our latest analysis for China Biotech Services Holdings
查看我們對中國生物技術服務控股公司的最新分析
Is There Enough Growth For China Biotech Services Holdings?
中國生物科技服務控股公司有足夠的增長嗎?
There's an inherent assumption that a company should far outperform the market for P/E ratios like China Biotech Services Holdings' to be considered reasonable.
有一種固有的假設,即一家公司的市盈率應該遠遠超過市場,才能被認為是合理的。
Retrospectively, the last year delivered a frustrating 2.6% decrease to the company's bottom line. At least EPS has managed not to go completely backwards from three years ago in aggregate, thanks to the earlier period of growth. Accordingly, shareholders probably wouldn't have been overly satisfied with the unstable medium-term growth rates.
回顧過去一年,該公司的利潤令人沮喪地下降了2.6%。至少,由於早期的增長,每股收益總體上沒有從三年前完全倒退。因此,股東們可能不會對不穩定的中期增長率過於滿意。
Comparing that to the market, which is predicted to deliver 16% growth in the next 12 months, the company's momentum is weaker based on recent medium-term annualised earnings results.
與預計未來12個月將實現16%增長的市場相比,根據最近的中期年化收益結果,該公司的增長勢頭較弱。
With this information, we find it concerning that China Biotech Services Holdings is trading at a P/E higher than the market. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. There's a good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with recent growth rates.
有了這些信息,我們發現中國生物技術服務控股公司的市盈率高於市場。顯然,該公司的許多投資者比最近的情況所顯示的要樂觀得多,不願以任何價格拋售他們的股票。如果市盈率下降到與最近的增長率更一致的水平,現有股東很可能會讓自己未來感到失望。
What We Can Learn From China Biotech Services Holdings' P/E?
我們可以從中國生物技術服務控股公司的市盈率中學到什麼?
China Biotech Services Holdings' P/E is flying high just like its stock has during the last month. While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.
中國生物技術服務控股公司的市盈率正在飆升,就像它的股票在過去一個月裏一樣。雖然市盈率不應該是你是否買入一隻股票的決定性因素,但它是一個很好的盈利預期晴雨表。
Our examination of China Biotech Services Holdings revealed its three-year earnings trends aren't impacting its high P/E anywhere near as much as we would have predicted, given they look worse than current market expectations. Right now we are increasingly uncomfortable with the high P/E as this earnings performance isn't likely to support such positive sentiment for long. Unless the recent medium-term conditions improve markedly, it's very challenging to accept these prices as being reasonable.
我們對中國生物科技控股有限公司的調查顯示,該公司三年的盈利趨勢對其高市盈率的影響並不像我們預期的那麼大,因為它們看起來比目前的市場預期更糟糕。目前,我們對高市盈率越來越感到不安,因為這種盈利表現不太可能長期支撐這種積極情緒。除非最近的中期狀況明顯改善,否則要接受這些價格是合理的是非常具有挑戰性的。
Don't forget that there may be other risks. For instance, we've identified 1 warning sign for China Biotech Services Holdings that you should be aware of.
別忘了,可能還有其他風險。例如,我們已經確定中國生物科技服務控股有限公司的1個警告標誌這一點你應該知道。
If you're unsure about the strength of China Biotech Services Holdings' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
如果你.不確定中國生物技術服務控股公司的業務實力,為什麼不探索我們的互動名單與堅實的業務基本面為其他一些公司,你可能有不及預期的期望。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧